Metastatic Ovarian Cancer - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 79 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Metastatic Ovarian Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Metastatic Ovarian Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Ovarian Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Ovarian Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Metastatic Ovarian Cancer - Overview 8
Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis 9
Metastatic Ovarian Cancer - Therapeutics under Development by Companies 10
Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 12
Metastatic Ovarian Cancer - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Metastatic Ovarian Cancer - Products under Development by Companies 16
Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes 17
Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development 18
F. Hoffmann-La Roche Ltd. 18
Sumitomo Dainippon Pharma Co., Ltd. 19
Millennium Pharmaceuticals, Inc. 20
Eisai Co., Ltd. 21
Northwest Biotherapeutics, Inc. 22
VG Life Sciences, Inc. 23
Immune Design Corp. 24
Aura Biosciences, Inc. 25
Metastatic Ovarian Cancer - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
bevacizumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
orteronel - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
antigen-presenting dendritic cells (living, autologous) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
E-7449 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DCVax-Direct - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Stem Cell Therapy for Oncology - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
hydroxychloroquine + sorafenib tosylate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LV-305 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
G-305 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Drugs for Metastatic Ovarian Cancer - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SM-276001 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Drugs for Cancer - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Metastatic Ovarian Cancer - Recent Pipeline Updates 57
Metastatic Ovarian Cancer - Dormant Projects 71
Metastatic Ovarian Cancer - Discontinued Products 72
Metastatic Ovarian Cancer - Product Development Milestones 73
Featured News & Press Releases 73
Mar 10, 2014: NW Bio Announces Two German Approvals: "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement 73
Jan 09, 2014: Synta Announces Launch of GANNET53, a Randomized, pan-European Study of Ganetespib in p53 Mutant, Metastatic Ovarian Cancer 74
Mar 18, 2013: Merrimack Pharma Completes Enrollment In Phase II Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-resistant Or Refractory Advanced Ovarian Cancers 75
Mar 06, 2013: Ziopharm Oncology Announces Initiation Of Indiana University-sponsored Phase II Study Of Palifosfamide In Recurrent And Incurable Germ Cell Tumors 76
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Of MM-121 At European Society For Medical Oncology 2012 76
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79

List of Tables
Number of Products under Development for Metastatic Ovarian Cancer, H2 2014 8
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Metastatic Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 18
Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 19
Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 20
Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2014 21
Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2014 22
Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H2 2014 23
Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H2 2014 24
Metastatic Ovarian Cancer - Pipeline by Aura Biosciences, Inc., H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Assessment by Combination Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 33
Number of Products by Stage and Route of Administration, H2 2014 35
Number of Products by Stage and Molecule Type, H2 2014 37
Metastatic Ovarian Cancer Therapeutics - Recent Pipeline Updates, H2 2014 57
Metastatic Ovarian Cancer - Dormant Projects, H2 2014 71
Metastatic Ovarian Cancer - Discontinued Products, H2 2014 72